Neurogene: Funding, Investors & Team (Oct 2026)
Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families. To do this, we are working with experts across the globe to advance a broad pipeline of programs to treat the underlying cause of serious neurological disorders and thereby address the overwhelming need for new therapies. Although the human genome was sequenced for the first time nearly 20 years ago, the true genomics revolution is taking place now, providing us with the ability to radically alter rare, genetic disorders. At Neurogene, we are working to provide medicines to improve the lives of neurologically-impaired and developmentally-delayed children and their families. We are building a team of passionate, driven individuals who envision a world in which all families have access to genetic medicines, even if the disorder is exceedingly rare. To learn more, please visit http://www.neurogene.com/careers/.
Neurogene has raised $200M across 1 funding round on record, the most recent an undisclosed round of $200M announced in Nov 2024.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Neurogene Company Profile and Key Stats
Latest funding round on record: Nov 2024.
Neurogene Funding Rounds
Neurogene Founders and Leadership Team
Contact details for the Neurogene team: 1 of 1 has an email address on file.
Start 14-day free trial →Neurogene Funding Compared to Other Biotechnology Startups
Neurogene's latest round of $200M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Neurogene in Biotechnology and New York
Companies Similar to Neurogene
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Neurogene Funding FAQs
What does Neurogene do?
Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families. To do this, we are working with experts across the globe to advance a broad pipeline of programs to treat the underlying cause of serious neurological disorders and thereby address the overwhelming need for new therapies. Although the human genome was sequenced for the first time nearly 20 years ago, the true genomics revolution is taking place now, providing us with the ability to radically alter rare, genetic disorders. At Neurogene, we are working to provide medicines to improve the lives of neurologically-impaired and developmentally-delayed children and their families. We are building a team of passionate, driven individuals who envision a world in which all families have access to genetic medicines, even if the disorder is exceedingly rare. To learn more, please visit http://www.neurogene.com/careers/.
How much funding has Neurogene raised?
Neurogene has raised $200M across 1 round on record. The most recent is an undisclosed round of $200M announced in Nov 2024.
When did Neurogene last raise funding?
Neurogene's most recent funding round on record is an undisclosed round of $200M, announced in Nov 2024.
Who founded Neurogene?
FundedIQ lists Rachel Mcminn (Founder) at Neurogene.
Where is Neurogene headquartered?
Neurogene is based in New York, United States.
How many employees does Neurogene have?
Neurogene is in the 51-100 employee band.
How does Neurogene's funding compare to other Biotechnology startups?
Neurogene's latest round of $200M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Neurogene Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Neurogene is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.